Renale Denervation

Zusammenfassung

Die katheterbasierte renale Denervation ist ein innovatives Verfahren, das eine neue Behandlungsoption bei therapierefraktärer Hypertonie darstellt. Auch wenn die Zahl der bisher behandelten Patienten noch nicht sehr groß ist, so sind die vorhandenen Daten vielversprechend. Dieser Artikel beschreibt die pathophysiologischen Hintergründe und Erklärungsansätze der Methode und fasst die aktuellen Studiendaten zusammen. Weiterhin werden die derzeit verfügbaren Systeme im Einzelnen vorgestellt und die praktische Umsetzung konkret beschrieben. Dabei werden alle zu berücksichtigenden Aspekte dargestellt und erläutert. Zuletzt werden die technischen Weiterentwicklungen und mögliche Ausweitungen der Indikation zur renalen Denervation diskutiert.

• Literatur

• 1 Lim SS, Vos T, Flaxman AD et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260
• 2 Meisinger C, Heier M, Völzke H et al. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006; 24: 293-299
• 3 Weinehall L, Ohgren B, Persson M et al. High remaining risk in poorly treated hypertension: the ‚rule of halves‘ still exists. J Hypertens 2002; 20: 2081-2088
• 4 Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-1762
• 5 Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117: e510-e526
• 6 Smith PA, Graham LN, Mackintosh AF et al. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 2004; 17: 217-222
• 7 Bruening F. Die operative Behandlung des Halsbrustsympathikus und Bemerkungen ueber die operative Behandlung der abnormen Blutdrucksteigerung. Klin Wochenschr 1923; 2: 777-780
• 8 Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1.266 cases. J Am Med Assoc 1953; 152: 1501-1504
• 9 Hart EC, Charkoudian N. Sympathetic neural mechanisms in human blood pressure regulation. Curr Hypertens Rep 2011; 13: 237-243
• 10 Vonend O, Rump LC, Ritz E. Sympathetic overactivity – the Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial 2008; 21: 326-330
• 11 Vonend O, Okonek A, Stegbauer J et al. Renovascular effects of sympathetic cotransmitters ATP and NPY are age-dependent in spontaneously hypertensive rats. Cardiovasc Res 2005; 66: 345-352
• 12 Vonend O, Habbel S, Stegbauer J et al. Alpha(2A)-adrenoceptors regulate sympathetic transmitter release in mice kidneys. Br J Pharmacol 2007; 150: 121-127
• 13 Vonend O, Oberhauser V, von Kügelgen I et al. ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells. Kidney Int 2002; 61: 1617-1626
• 14 Oberhauser V, Vonend O, Rump LC. Neuropeptide Y and ATP interact to control renovascular resistance in the rat. J Am Soc Nephrol 1999; 10: 1179-1185
• 15 Carlson SH, Wyss JM. Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action. Curr Hypertens Rep 2008; 10: 233-240
• 16 Campese VM. Neurogenic factors and hypertension in renal disease. Kidney Int Suppl 2000; 75: 2-6
• 17 Converse Jr RL, Jacobsen TN, Toto RD et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918
• 18 Hausberg M, Kosch M, Harmelink P et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106: 1974-1979
• 19 Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol 2009; 54: 375-385
• 20 Oda Y, Asanoi H, Ueno H et al. Pulse-synchronous sympathetic burst power as a new index of sympathoexcitation in patients with heart failure. Am J Physiol Heart Circ Physiol 2004; 287: H1821-H1827
• 21 Pedrosa RP, Drager LF, Gonzaga CC et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58: 811-817
• 22 Silverberg DS, Oksenberg A, Iaina A. Sleep-related breathing disorders as a major cause of essential hypertension: fact or fiction?. Curr Opin Nephrol Hypertens 1998; 7: 353-357
• 23 Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand 2003; 177: 385-390
• 24 Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension 2011; 58: 559-565
• 25 Page IH, Heuer GJ. The effect of renal denervation on patients suffering from nephritis. J Clin Invest 1935; 14: 443-458
• 26 Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934
• 27 Krum H. Long-term follow-up of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction. ACC 2012, March 24–27, Chicago (USA)
• 28 Symplicity HTN-2 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-917
• 29 Esler MD, Krum H. Symplicity HTN-2 Investigators et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909
• 30 Schmieder RE, Redon J, Grassi G et al. ESH position paper: renal denervation – an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841
• 31 Mahfoud F, Vonend O, Bruck H et al. Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment. Dtsch Med Wochenschr 2011; 136: 2418
• 32 Vonend O, Antoch G, Rump LC et al. Secondary rise in blood pressure after renal denervation. Lancet 2012; 380: 778
• 33 Kandzari DE, Bhatt DL, Sobotka PA et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol 2012; 35: 528-535
• 34 Ahmed H, Neuzil P, Skoda J et al. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv 2012; 5: 758-765
• 35 Bunte MC, Infante de Oliveira E, Shishehbor MH. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv 2013; 6: 1-9
• 36 Pollak R, Prusak BF, Mozes MF. Anatomic abnormalities of cadaver kidneys procured for purposes of transplantation. Am Surg 1986; 52: 233-235
• 37 Steigerwald K, Titova A, Malle C et al. Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens 2012; 30: 2230-2239
• 38 Mahfoud F, Schlaich M, Kindermann I et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation 2011; 123: 1940-1946
• 39 Vink EE, de Jager RL, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options. Curr Hypertens Rep 2013; 15: 95-101
• 40 Sobotka PA, Krum H, Böhm M et al. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep 2012; 14: 285-292
• 41 Geisler BP, Egan BM, Cohen JT et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol 2012; 60: 1271-1277
• 42 Hoppe UC et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012; 6: 270-276